| ［1］ |
中华医学会皮肤性病学分会药物不良反应研究中心. Stevens⁃Johnson综合征/中毒性表皮坏死松解症诊疗专家共识［J］. 中华皮肤科杂志, 2021,54（5）:376⁃381. doi: 10.35541/cjd.20201177.
|
| ［2］ |
Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions［J］. J Clin Invest, 2018,128（3）:985⁃996. doi: 10.1172/JCI93349.
|
| ［3］ |
Hasegawa A, Abe R. Recent advances in managing and understanding Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. F1000Res, 2020,9:612. doi: 10.12688/f1000research. 24748.1.
|
| ［4］ |
Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis with meta⁃regression of observational studies［J］. Int J Dermatol, 2015,54（1）:108⁃115. doi: 10.1111/ijd.12423.
|
| ［5］ |
Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti⁃TNF⁃alpha treatment［J］. J Allergy Clin Immunol, 2005,116（4）:923⁃924. doi: 10.1016/j.jaci.2005.06.029.
|
| ［6］ |
Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis［J］. J Am Acad Dermatol, 2014,71（2）:278⁃283. doi: 10.1016/j.jaad.2014.04.044.
|
| ［7］ |
Pham CH, Gillenwater TJ, Nagengast E, et al. Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. Burns, 2019,45（7）:1634⁃1638. doi: 10.1016/j.burns.2018.12.018.
|
| ［8］ |
Gaitanis G, Spyridonos P, Patmanidis K, et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high⁃dose intravenous immunoglobulin［J］. Dermatology, 2012,224（2）:134⁃139. doi: 10.1159/000338202.
|
| ［9］ |
Zárate⁃Correa LC, Carrillo⁃Gómez DC, Ramírez⁃Escobar AF, et al. Toxic epidermal necrolysis successfully treated with infliximab［J］. J Investig Allergol Clin Immunol, 2013,23（1）:61⁃63.
|
| ［10］ |
Chafranska L, Saunte DM, Behrendt N, et al. Pediatric toxic epidermal necrolysis treated successfully with infliximab［J］. Pediatr Dermatol, 2019,36（3）:342⁃345. doi: 10.1111/pde.13778.
|
